Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of docetaxel + oxaliplatin + capecitabine in untreated advanced or metastatic gastric cancer
2011-001720-37Phase 2Completed
- Sponsor
- Centro di Riferimento Oncologico di Aviano
- Start
- Dec 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, oxaliplatin and capecitabine in gastric adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by Centro di Riferimento Oncologico di Aviano. Primary endpoint: Response rate. Started Dec 2011; status: completed.
02
Drugs
docetaxeloxaliplatincapecitabine
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2011-001720-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001720-37.